Safety Study of Ranibizumab Eye Injections to Treat Choroidal Neovascularization That Was Caused Other Than by Age-Related Macular Degeneration.

Sponsor
Ophthalmic Consultants of Boston
Study ID
NCT00395551
Phase
PHASE1
Status
Completed

Conditions

  • Choroidal Neovascularization

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Accepted

Interventions

Study Details

The purpose of this study is to determine whether ranibizumab is effective in the treatment of choroidal neovascularization secondary to causes other then wet macular-degeneration.

Key Dates

First listed
Nov 3, 2006
Start date
Dec 31, 2005
Status verified
Jan 2010
Primary completion
Jun 30, 2009
Completion
Jun 30, 2009

Study Design

Enrollment
30 participants (estimated)
Allocation
RANDOMIZED
Intervention model
FACTORIAL
Primary purpose
TREATMENT

Arms

  • Active Comparator: ranibizumab
    ranibizumab 0.5mg intravitreal injection

Primary Outcome Measure

The primary outcome measures for safety and tolerability [ Time Frame: Mean change in visual acuity from baseline to 6 months & 12 months ]

Related Studies